Savara Inc. (SVRA)
NASDAQ: SVRA
· Real-Time Price · USD
2.40
-0.09 (-3.61%)
At close: Jun 05, 2025, 3:59 PM
2.41
0.63%
After-hours: Jun 05, 2025, 07:44 PM EDT
-3.61% (1D)
| Bid | 2.38 |
| Market Cap | 413.94M |
| Revenue (ttm) | 272K |
| Net Income (ttm) | -102.17M |
| EPS (ttm) | -0.49 |
| PE Ratio (ttm) | -4.89 |
| Forward PE | -5.09 |
| Analyst | Buy |
| Ask | 2.51 |
| Volume | 844,483 |
| Avg. Volume (20D) | 1,515,698 |
| Open | 2.48 |
| Previous Close | 2.49 |
| Day's Range | 2.33 - 2.50 |
| 52-Week Range | 1.89 - 5.11 |
| Beta | 0.32 |
About SVRA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SVRA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SVRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+9.79%
Savara shares are trading higher. Guggenheim maint...
Unlock content with
Pro Subscription
1 week ago
-31.69%
Savara shares are trading lower after the company announced it received a refusal to file letter from the FDA for its biologics license application.
1 week ago · accessnewswire.com
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky InvestigatesNEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...
2 weeks ago · businesswire.com
Savara Announces Participation in Jefferies Global Healthcare ConferenceLANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management te...
